Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Akira Kazama"'
Autor:
Masaki Murata, Vladimir Bilim, Yuko Shirono, Akira Kazama, Kaede Hiruma, Masayuki Tasaki, Yoshihiko Tomita
Publikováno v:
Current Issues in Molecular Biology, Vol 45, Iss 9, Pp 7432-7448 (2023)
The prognosis of patients with advanced renal cell carcinoma (RCC) has improved with newer therapies, including molecular-targeted therapies and immuno-oncology agents. Despite these therapeutic advances, many patients with metastatic disease remain
Externí odkaz:
https://doaj.org/article/9ac6ea5ad56e4068bf42bd8b1f8af74a
Autor:
Tsutomu Anraku, Masaki Murata, Hiroo Kuroki, Akira Kazama, Yuko Shirono, Masayuki Tasaki, Vladimir Bilim, Yoshihiko Tomita
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 7, p 704 (2024)
Despite significant advancements in systemic therapy for renal cell carcinoma (RCC), the prognosis for patients with metastatic RCC remains poor, as they are often incurable. Consequently, there is an urgent need for innovative therapeutic strategies
Externí odkaz:
https://doaj.org/article/83968521b1884b3fa8b0b1a0c4c0351c
Autor:
Worapat Attawettayanon, Yosuke Yasuda, JJ H. Zhang, Akira Kazama, Nityam Rathi, Carlos Munoz-Lopez, Kieran Lewis, Snehi Shah, Jianbo Li, João Pedro Emrich Accioly, Rebecca A. Campbell, Shetal Shah, Andrew Wood, Jihad Kaouk, Georges-Pascal Haber, Mohamad Eltemamy, Venkatesh Krishnamurthi, Robert Abouassaly, Christopher Weight, Ithaar Derweesh, Steven C. Campbell
Publikováno v:
European Urology Open Science, Vol 54, Iss , Pp 1-9 (2023)
Background: Partial nephrectomy (PN) is preferred for a renal mass in a solitary kidney (RMSK), although tumors with high complexity can be challenging. Objective: To evaluate the evolution of RMSK management with a focus on achievement of PN. Design
Externí odkaz:
https://doaj.org/article/01565f9f554f47bd8902b8941ad4006b
Autor:
Yuko Shirono, Vladimir Bilim, Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita
Publikováno v:
Current Oncology, Vol 30, Iss 6, Pp 5350-5365 (2023)
Advanced bladder cancer (BC) (local invasive and/or metastatic) is not curable even with cytotoxic chemotherapy, immune checkpoint inhibitors, and targeted treatment. Targeting GSK-3β is a promising novel approach in advanced BC. The induction of au
Externí odkaz:
https://doaj.org/article/928668710b4b4b77a11f83773094fb54
Autor:
Akira Kazama, Vladimir Bilim, Masayuki Tasaki, Tsutomu Anraku, Hiroo Kuroki, Yuko Shirono, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Immune checkpoint inhibitors (ICI) have dramatically changed the treatment of metastatic renal cell carcinoma (mRCC). Although many studies have reported biomarkers as predicting the efficacy of ICI in mRCC, they remain controversial and hav
Externí odkaz:
https://doaj.org/article/21fdee8a2293495b97344d87f8c97253
Autor:
Hiroo Kuroki, Tsutomu Anraku, Akira Kazama, Vladimir Bilim, Masayuki Tasaki, Daniel Schmitt, Andrew P. Mazar, Francis J Giles, Andrey Ugolkov, Yoshihiko Tomita
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Abstract Glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase, has been identified as a potential therapeutic target in human bladder cancer. In the present study, we investigated the antitumor effect of a small molecule GSK-3β inhib
Externí odkaz:
https://doaj.org/article/1423d830529042219401ce10296db960
Autor:
Takashi Ando, Akira Kazama
Publikováno v:
Urology Case Reports, Vol 39, Iss , Pp 101759- (2021)
Transurethral double J (DJ) stent placement is a standard method for drainage during ureteral obstruction caused by a ureteral stone and for the management of complications after transurethral ureterolithotripsy (TUL). This is a safe and minimally in
Externí odkaz:
https://doaj.org/article/d56658e798944d458d25ec13e9e6d983
Autor:
Kazutoshi Fujita, Go Kimura, Toyonori Tsuzuki, Taigo Kato, Eri Banno, Akira Kazama, Ryo Yamashita, Yuto Matsushita, Daisuke Ishii, Tomoya Fukawa, Yuki Nakagawa, Tamaki Fukuyama, Fumikazu Sano, Yukihiro Kondo, Hirotsugu Uemura
Publikováno v:
Cancers, Vol 14, Iss 21, p 5258 (2022)
Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions an
Externí odkaz:
https://doaj.org/article/3f257d107e96401d972193339d0c113d
Autor:
Akira Kazama, Toshihiro Saito, Keisuke Takeda, Kazuhiro Kobayashi, Toshiki Tanikawa, Ayae Kanemoto, Fumio Ayukawa, Yasuo Matsumoto, Tadashi Sugita, Noboru Hara, Yoshihiko Tomita
Publikováno v:
Prostate Cancer, Vol 2019 (2019)
Background. To predict long-term treatment outcome of radiation therapy (RT) plus androgen deprivation therapy (ADT) for high-risk locally advanced prostate cancer. Methods. In total, 204 patients with the National Comprehensive Cancer Network (NCCN)
Externí odkaz:
https://doaj.org/article/55941222953748f5aca2879b6133b70e
Autor:
Tsutomu Anraku, Masaki Murata, Hiroo Kuroki, Akira Kazama, Yuko Shirono, Masayuki Tasaki, Vladimir Bilim, Yoshihiko Tomita
Background: Despite advances in systemic therapy for renal cell carcinoma (RCC), most metastatic RCCs remain incurable. Therefore, new therapeutic approaches are needed to further improve the outcome of RCC treatment. Methods: We treated cultured RCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de4faf3f0a4536c3f7b86531c36e0370
https://doi.org/10.21203/rs.3.rs-2287954/v1
https://doi.org/10.21203/rs.3.rs-2287954/v1